Measles, Mumps and Rubella (MMR) vaccine

This procurement, from a United Kingdom contracting authority, is for the supply of Measles, Mumps, and Rubella (MMR) vaccine, with supply expected from 2027. The tender aims to secure a consistent and reliable source of this critical combination vaccine, essential for national immunisation programmes. Bidders must be manufacturers or authorised distributors with the capacity to meet substantial volume requirements and maintain strict cold chain integrity throughout the supply process. Key requirements will include demonstrating adherence to Good Manufacturing Practices (GMP), holding relevant regulatory approvals from the UK's MHRA, and providing comprehensive product information, including efficacy and safety data. The tender documentation will detail specific product specifications, packaging requirements, delivery schedules, and quality assurance protocols. Experience in supplying vaccines to public health bodies or large healthcare systems is a significant advantage. The contract will likely involve ongoing supply, necessitating a robust supply chain and logistical capability to ensure timely delivery to designated vaccination sites across the United Kingdom.